Oxford BioDynamics Plc (AIM:OBD)
London · Delayed Price · Currency is GBP · Price in GBX 0.1400
+0.0150 (12.00%)
Jul 24, 2026, 4:21 PM GMT
Oxford BioDynamics Revenue
Oxford BioDynamics had revenue of 687.00K GBP in the half year ending March 31, 2026, with 110.09% growth. This brings the company's revenue in the last twelve months to 1.20M, up 33.37% year-over-year. In the fiscal year ending September 30, 2025, Oxford BioDynamics had annual revenue of 1.10M with 72.17% growth.
Revenue (ttm)
1.20M
Revenue Growth
+33.37%
P/S Ratio
4.49
Revenue / Employee
32.30K
Employees
37
Market Cap
5.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.10M | 459.00K | 72.17% |
| Sep 30, 2024 | 636.00K | 126.00K | 24.71% |
| Sep 30, 2023 | 510.00K | 356.00K | 231.17% |
| Sep 30, 2022 | 154.00K | -187.00K | -54.84% |
| Sep 30, 2021 | 341.00K | -115.00K | -25.22% |
| Sep 30, 2020 | 456.00K | -451.00K | -49.72% |
| Sep 30, 2019 | 907.00K | -279.00K | -23.52% |
| Sep 30, 2018 | 1.19M | 3.00K | 0.25% |
| Sep 30, 2017 | 1.18M | 92.00K | 8.43% |
| Sep 30, 2016 | 1.09M | 389.00K | 55.41% |
| Sep 30, 2015 | 702.00K | 43.00K | 6.53% |
| Sep 30, 2014 | 659.00K | 309.00K | 88.29% |
| Sep 30, 2013 | 350.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| Futura Medical | 1.70M |
| Fusion Antibodies | 1.60M |
| OptiBiotix Health | 1.17M |
| Physiomics | 1.01M |
| Genflow Biosciences | 585.61K |
| CRISM Therapeutics | 231.00K |
| Thalia Therapeutics | 7.26K |
Oxford BioDynamics News
- 2 years ago - Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA. - Business Wire
- 2 years ago - Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy - Business Wire